Non-Melanoma Skin Cancers Coverage from Every Angle

ESMO 2018: Sonidegib Treatment in Advanced Basal Cell Carcinoma

By: Kayci Reyer
Posted: Monday, October 29, 2018

Patients with advanced basal cell carcinoma saw a long duration of response as well as improved or maintained quality of life when undergoing sonidegib treatment, according to research recently presented at the European Society for Medical Oncology 2018 Congress in Munich (Abstract 1295P). Michael R. Migden, MD, of MD Anderson Cancer Center, noted that the 12- and 30-month quality-of-life outcomes remained consistent with those from the primary data previously reported.

The randomized phase II BOLT study included 230 patients with both localized (n = 194) and metastatic (n = 36) basal cell carcinoma who were candidates for neither curative surgery nor radiation; none of them had received prior treatment. Participants received an oral dose of either 200 mg or 800 mg of sonidegib once daily, and results were recorded at follow-up intervals of 6, 12, 18, 30, and 42 months.

For patients with localized basal cell carcinoma, the median duration of response at a follow-up of 42 months was 26.1 months for those receiving 200-mg of sonidegib daily versus 23.3 months for those receiving 800 mg daily. The objective response rate was higher in the group taking 200 mg daily.

For patients with metastatic basal cell carcinoma, the median duration of response at a follow-up of 42 months was 24 months for those taking 200 mg of sonidegib daily but was inestimable for those taking 800 mg daily. Unlike the results in the localized cohort, those patients treated with 200 mg experienced a lower objective response rate than those treated with 800 mg. The majority of patients in both the 200-mg and 800-mg dosage groups saw an improved or maintained quality of life during treatment.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.